IL-13: The Core Driver of Type 2 Immune Response and a Key Target in Multiple Disease Areas
Author: Senior Product Manager of UA Views：6 
This article systematically elaborates on the molecular characteristics and biological functions of IL-13, focusing on its role as a core member of the Th2 cytokine family in activating the JAK-STAT signaling pathway through the type II receptor complex. It analyzes its pathogenic role in type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic sinusitis with nasal polyps, and explores its upregulated expression in the tumor microenvironment and potential as an immunotherapy target.
- Recent Advances
- Product Information
Recent Advances
IL-13: The Core Driver of Type 2 Immune Response and a Key Target in Multiple Disease Areas
Overview
This article systematically elaborates on the molecular characteristics and biological functions of IL-13, focusing on its role as a core member of the Th2 cytokine family. It details its molecular mechanism of activating the JAK-STAT signaling pathway through the type II receptor complex, analyzes its pathogenic role in type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, and explores its upregulated expression in the tumor microenvironment and potential as an immunotherapy target.
This article systematically elaborates on the molecular characteristics and biological functions of IL-13, focusing on its role as a core member of the Th2 cytokine family. It details its molecular mechanism of activating the JAK-STAT signaling pathway through the type II receptor complex, analyzes its pathogenic role in type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, and explores its upregulated expression in the tumor microenvironment and potential as an immunotherapy target.
I. Molecular Characteristics and Cellular Sources of IL-13
Interleukin-13 (IL-13) is a core member of the T helper 2 (Th2) cytokine family, consisting of approximately 132 amino acid residues and functioning as a secreted glycoprotein with a molecular weight of about 12 to 16 kDa. The IL-13 gene is located on human chromosome 5q31.1, closely linked to the IL-4 gene, with which it shares high homology in both gene structure and amino acid sequence, both adopting a four α-helix bundle folding pattern. IL-13 is primarily produced by activated Th2 cells, with other significant sources including type 2 innate lymphoid cells (ILC2s), eosinophils, and mast cells. In mucosal tissues, airway epithelial cells and ILC2s can rapidly secrete IL-13 upon stimulation by allergens or pathogens. The expression of IL-13 is precisely regulated by transcription factors GATA3 and STAT6, playing a central role in Th2-type immune responses.
II. Receptor System and Signal Transduction Mechanism of IL-13
IL-13 initiates signal transduction by binding to receptor complexes on the surface of target cells. Unlike IL-4, which can bind to both type I and type II receptor complexes, IL-13 exclusively binds to the type II receptor complex. The type II receptor consists of two subunits, IL-4Rα and IL-13Rα1, serving as a shared signaling platform for IL-4 and IL-13, primarily expressed on non-hematopoietic cells such as epithelial cells, fibroblasts, and smooth muscle cells. Upon binding of IL-13 to IL-13Rα1, IL-4Rα is recruited to form a high-affinity heterodimeric complex, activating Janus family kinases (primarily JAK1 with JAK3 or JAK1 with TYK2), which subsequently phosphorylate signal transducer and activator of transcription 6 (STAT6). The phosphorylated STAT6 forms homodimers and translocates to the nucleus, initiating transcription of downstream target genes. The JAK-STAT signaling pathway activated through this complex primarily drives type 2 inflammatory effects, including mucus secretion, mucosal barrier inflammation, tissue remodeling, and eosinophil recruitment.
III. Pathogenic Role of IL-13 in Type 2 Inflammatory Diseases
Under normal conditions, IL-13 receptor subunits are expressed at low levels to ensure moderate regulation of type 2 immune responses. However, as a key cytokine in inducing and maintaining type 2 inflammatory reactions, IL-13 is closely associated with various atopic diseases. In atopic dermatitis, IL-13 directly disrupts epidermal barrier function by downregulating the expression of barrier-related proteins such as filaggrin in keratinocytes, while amplifying inflammatory cascades and itch signaling. In asthma, IL-13 induces excessive airway mucus secretion, airway hyperresponsiveness, and eosinophil infiltration, directly contributing to airway obstruction and respiratory dysfunction. In chronic rhinosinusitis with nasal polyps, IL-13 promotes chronic inflammation and polyp formation in the nasal mucosa. The overexpression of IL-13 in these diseases constitutes the core pathological driver of type 2 inflammation.
IV. Context-Dependent Functions of IL-13 and Its Association with Tumors
The functions of cytokines exhibit significant context dependence. In rheumatoid arthritis, a primarily Th1/Th17-driven autoimmune disease, IL-4 demonstrates notable anti-inflammatory properties by inhibiting synovial cells from producing pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-α. This phenomenon highlights the plasticity of cytokine functions in different immune contexts. In cancer research, upregulated expression of IL-4Rα and IL-13Rα1 has been observed on the surface of various tumor cells (e.g., glioblastoma, breast cancer, lymphoma), which is not only associated with tumor progression but also represents a potential target for immunotherapy. The binding of IL-13 to its receptors on tumor cells activates signaling pathways such as JAK-STAT6 and PI3K-AKT, promoting tumor cell proliferation, survival, and metastasis, while also facilitating immune evasion by reshaping the immune cell composition in the tumor microenvironment.
V. Therapeutic Strategies Targeting the IL-13 Signaling Pathway
Given the central role of IL-13 in type 2 inflammatory diseases, targeting the IL-13 signaling pathway has become a key strategy for treating conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Several anti-IL-13 antibody drugs (e.g., lebrikizumab, tralokinumab) and IL-4Rα-blocking antibodies (e.g., dupilumab) have been approved for clinical use. These drugs effectively mitigate type 2 inflammatory responses by blocking the binding of IL-13 to its receptors or inhibiting receptor signal transduction. In the field of oncology, antibody-drug conjugates and chimeric antigen receptor T-cell strategies targeting IL-4Rα or IL-13Rα1 are in preclinical and early clinical development stages, aiming to achieve precise tumor targeting by leveraging the selective overexpression of these receptors on tumor cells.
VI. Conclusion
As a core effector molecule of Th2-type immune responses, IL-13 plays an irreplaceable and critical role in the pathological processes of type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, through its precise mechanism of activating the JAK-STAT6 signaling pathway via the type II receptor complex. Its upregulated expression in the tumor microenvironment further expands its potential as a target for immunotherapy. IL-13 Protein, Mouse provides essential tool support for in-depth analysis of IL-13's functional networks in type 2 immunity and tumor progression, as well as for the development of related therapeutic strategies.
In IL-13-related basic research and drug screening, high-quality recombinant IL-13 protein is a core tool for receptor binding assays, cellular functional studies, and signal pathway analysis. To meet this research demand, Uni offers IL-13 Protein, Mouse, suitable for applications such as studying type 2 immune responses in mice, exploring the mechanisms of the IL-13/STAT6 signaling pathway, and evaluating the in vitro activity of anti-IL-13 antibody drugs.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161
Product Information
Link：
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy 
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
Business license (three certificates in one) Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.
